Home Stock

Stock Research: Charles River Laboratories

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Charles River Laboratories

NYQ:CRL US1598641074
71
  • Value
    43
  • Growth
    66
  • Safety
    Safety
    74
  • Combined
    71
  • Sentiment
    49
  • 360° View
    360° View
    71
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Charles River Laboratories International, Inc. is a drug development company that provides essential products and services globally to accelerate research and drug development. Its main businesses include Research Models and Services (Research Models, Research Model Services, Cell Solutions), Discovery and Safety Assessment (regulated and non-regulated DSA services, therapeutic discovery and optimization, in vitro and in vivo studies, laboratory support, consulting), and Manufacturing Solutions (Microbial Solutions, Biologics Solutions). It operates around the globe. In the last fiscal year, the company had 18600 employees, a market cap of $7584 million, profits of $1408 million, and revenue of $4050 million.

more

ANALYSIS: With an Obermatt 360° View of 71 (better than 71% compared with alternatives), overall professional sentiment and financial characteristics for the stock Charles River Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Charles River Laboratories. The consolidated Growth Rank has a good rank of 66, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 66% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 74 which means that the company has a financing structure that is safer than 74% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 43 which means that the share price of Charles River Laboratories is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 57% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Life Sciences Tools & Services
Size X-Large
Website criver.com
Index
D.J. US Health Care
S&P 500
Charles River Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
43 63 51 37
Growth
66 29 31 55
Safety
Safety
74 42 20 12
Sentiment
49 19 86 43
360° View
360° View
71 12 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 3 70 57
Opinions Change
50 13 36 60
Pro Holdings
n/a 74 88 21
Market Pulse
17 26 67 58
Sentiment
49 19 86 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
43 63 51 37
Growth
66 29 31 55
Safety Safety
74 42 20 12
Combined
71 23 12 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
86 63 57 67
Price vs. Earnings (P/E)
14 73 68 45
Price vs. Book (P/B)
70 53 40 22
Dividend Yield
1 1 1 1
Value
43 63 51 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
36 42 23 42
Profit Growth
91 22 48 57
Capital Growth
86 63 25 30
Stock Returns
22 25 61 81
Growth
66 29 31 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
18 28 20 22
Refinancing
91 31 9 17
Liquidity
79 55 71 56
Safety Safety
74 42 20 12

Similar Stocks

Discover high‑ranked alternatives to Charles River Laboratories and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Academy Sports and Outdoors

NSQ:ASO
Country: USA
Industry: Specialty Stores
Size: Large
Full Stock Analysis

Stewart Information

NYQ:STC
Country: USA
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

Revvity

NYQ:RVTY
Country: USA
Industry: Life Sciences Tools & Services
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews